Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation.

Kaur, J; Gulati, M; Kumar Jha, N; Disouza, J; Patravale, V; Dua, K; Kumar Singh, S

Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation.

Kaur, J Gulati, M Kumar Jha, N Disouza, J Patravale, V Dua, K

Kumar Singh, S

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Drug Discov Today, 2022
Issue Date:: 2022-02-11

Closed Access

	Filename	Description	Size
	1-s2.0-S1359644622000459-main.pdf	Published version	1.94 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kaur, J
dc.contributor.author	Gulati, M
dc.contributor.author	Kumar Jha, N
dc.contributor.author	Disouza, J
dc.contributor.author	Patravale, V
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Kumar Singh, S
dc.date.accessioned	2022-02-18T02:58:13Z
dc.date.available	2022-02-08
dc.date.available	2022-02-18T02:58:13Z
dc.date.issued	2022-02-11
dc.identifier.citation	Drug Discov Today, 2022
dc.identifier.issn	1359-6446
dc.identifier.issn	1878-5832
dc.identifier.uri	http://hdl.handle.net/10453/154681
dc.description.abstract	Polymeric micelles (PMs) have been explored pre-clinically for the delivery of chemotherapeutics to treat cancer. Their unique features, such as easy surface functionalization, stimuli-responsiveness, good stability, ability to modify drug release, enhanced permeation and retention effect, and potential to encapsulate more than one type of therapeutic molecules at a time, make them unique carriers for the targeted delivery or for enhancing the bioavailability of chemotherapeutics. PMs can also be used as theranostic nanocarriers for the mapping of drug therapy along with tumor imaging in patients with cancer. This review focuses on the limitations of existing treatment strategies and on innovative approaches employed for the functionalization of PMs for targeting cancer cells. In addition, the bottlenecks associated with the translation of PMs from the laboratory to clinics are also discussed.
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Drug Discov Today
dc.relation.isbasedon	10.1016/j.drudis.2022.02.005
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.title	Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-02-18T02:58:12Z
pubs.publication-status	Published online

Abstract:

Polymeric micelles (PMs) have been explored pre-clinically for the delivery of chemotherapeutics to treat cancer. Their unique features, such as easy surface functionalization, stimuli-responsiveness, good stability, ability to modify drug release, enhanced permeation and retention effect, and potential to encapsulate more than one type of therapeutic molecules at a time, make them unique carriers for the targeted delivery or for enhancing the bioavailability of chemotherapeutics. PMs can also be used as theranostic nanocarriers for the mapping of drug therapy along with tumor imaging in patients with cancer. This review focuses on the limitations of existing treatment strategies and on innovative approaches employed for the functionalization of PMs for targeting cancer cells. In addition, the bottlenecks associated with the translation of PMs from the laboratory to clinics are also discussed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/154681